[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$zldpf Graphic](https://lunarcrush.com/gi/w:26/t:$zldpf.png) $zldpf

Eli Lilly's new study on LY4065967 shows promise, while the market also reacts to the potential risks of compounded GLP-1 alternatives.

### About $zldpf
A pharmaceutical company's stock ticker symbol.  

### Insights [#](/topic/$zldpf/insights)
- $zldpf mentions is at XXX which is XXX% higher than it's daily average.
- $zldpf mentions near a 52-week high at XXX.
- $zldpf mentions is up XXX% from the previous month.
- $zldpf Engagements hit a high of XXXXXX for the day
- $zldpf Engagements hit an all time of XXXXXX for the day
- $zldpf Mentions hit a high of XXX for the day
- $zldpf Mentions hit an all time of XXX for the day

### Engagements: XXXXXX [#](/topic/$zldpf/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$zldpf/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$zldpf/time-series/interactions.tsv)  
**Current Value**: XXXXXX  
**Daily Average**: XXXXX  
**1 Month**: XXXXXX +297%  
**1-Year High**: XXXXXX on 2025-07-17  
**1-Year Low**: X on 2025-05-07  

| Social Network | X      |
| -------------- | -      |
| Engagements    | XXXXXX |
  

  
  
### Mentions: XXX [#](/topic/$zldpf/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$zldpf/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$zldpf/time-series/posts_active.tsv)  
**Current Value**: XXX  
**Daily Average**: XX  
**1 Week**: XXX +281%  
**1 Month**: XXX +303%  
**1-Year High**: XXX on 2025-07-17  
**1-Year Low**: X on 2025-05-07  

| Social Network | X   |
| -------------- | -   |
| Mentions       | XXX |
  

  
  
### Creators: X [#](/topic/$zldpf/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$zldpf/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$zldpf/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $zldpf in the last XX hours which is up XXX% from X in the previous XX hours
**Daily Average**: X  
**1 Week**: X -XX%  
**1 Month**: X -XX%  
**1-Year High**: X on 2025-05-01  
**1-Year Low**: X on 2025-05-07  

The most influential creators that mention $zldpf in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) | X    | XXXXX     | XX    | XXXXXX      |

[View More](/list/creators/$zldpf/100)
  
  
### Sentiment: XX% [#](/topic/$zldpf/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$zldpf/c:line/m:sentiment.svg)  
[Sentiment 24-Hour Chart Data](/topic/$zldpf/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Month**: XX% +18%  
**1-Year High**: XXX% on 2025-06-13  
**1-Year Low**: XX% on 2025-06-24  

**Most Supportive Themes**
- **GLP-1 Agonists' Broad Benefits:** (40%) The potential of GLP-1 receptor agonists in treating various conditions beyond diabetes and obesity, including cardiovascular health, and neurodegenerative diseases.
- **GLP-1 Drug Development and Investment:** (30%) The increasing interest and investment in GLP-1 drugs and related research, including new studies and developments by companies like Eli Lilly and Amgen.
- **Weight Loss and Hormonal Benefits:** (15%) The impact of GLP-1 drugs on weight loss and the potential for hormonal benefits, such as increased testosterone levels.
  
**Most Critical Themes**
- **GLP-1 Drug Risks and Drawbacks:** (15%)  Concerns about side effects, long-term efficacy, and potential risks associated with GLP-1 drugs and compounded alternatives.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| X       | XXXXX    | XX% | XXXXXX  | XX% | XXXXX    | XX% |
|         |          |     |         |     |          |     |
| Total   | XXXXX    | XX% | XXXXXX  | XX% | XXXXX    | XX% |
  


**Top assets mentioned**
In the posts about $zldpf in the last XX hours

[Hims & Hers Health, Inc. (HIMS)](/topic/$hims)
[Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn)
[Eli Lilly and Company (LLY)](/topic/$lly)

**Top topics mentioned**
In the posts about $zldpf in the last XX hours

[manat](/topic/manat), [$vani](/topic/$vani), [$hims](/topic/$hims), [hims](/topic/hims), [$rhhby](/topic/$rhhby), [$him](/topic/$him), [gibraltar pound](/topic/gibraltar-pound), [new era](/topic/new-era), [pfe](/topic/pfe), [$regn](/topic/$regn), [eli](/topic/eli), [$lly](/topic/$lly)

### Top Social Posts [#](/topic/$zldpf/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"🦉 With the study launched in late June early metabolic data could shape investor expectations. If absorption and excretion align the asset may gain strategic weight in Eli Lillys early pipeline. $LLY $NVO $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946006834348761373) 2025-07-18 00:39:19 UTC 4968 followers, XXX engagements


"🦉 Eli Lilly is testing LY4065967 in a Phase X trial focused on how the drug behaves inside the bodyabsorption breakdown and elimination. It uses a radiolabeled version to track every move. Two dosing formats reveal how much actually gets used. $LLY $NVO $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946006832423854403) 2025-07-18 00:39:18 UTC 4962 followers, XXX engagements


"💼Eli Lillys New Study on LY4065967: Key Insights for Investors $LLY $NVO $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1946006830263476425) 2025-07-18 00:39:18 UTC 4968 followers, XXX engagements


"🦉 Tirzepatide adds GIP receptor activation lowering IL-5 and IL-13 in asthma and cutting apnea events by over 25/hour in obesity-related sleep apnea. Effects appear partly independent of weight loss. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #respiratory #GLP1"  
[@AponiaAnalytics](/creator/x/AponiaAnalytics) on [X](/post/tweet/1945932790437941407) 2025-07-17 19:45:05 UTC 4962 followers, XXX engagements